04:06 AM EDT, 08/09/2024 (MT Newswires) -- Genmab A/S ( GMAB ) reported interim Q2 diluted earnings Thursday of 21.70 Danish kroner ($3.18), up from 20.28 Danish kroner a year earlier.

Analysts polled by Capital IQ expected 22.79 Danish kroner.

Revenue for the quarter ended June 30 was 5.4 billion Danish kroner, up from 4.17 billion Danish kroner a year earlier.

Analysts polled by Capital IQ expected 4.98 billion Danish kroner.

The company increased its 2024 revenue guidance to 20.5 billion to 21.7 billion Danish kroner from 18.7 billion to 20.5 billion Danish kroner previously. Analysts surveyed by Capital IQ expect 20.04 billion Danish kroner.

Price: 26.65, Change: -0.42, Percent Change: -1.55